Jyothy Labs (532926) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 revenue grew 8% year-over-year to ₹742 crore, with volume up 10.8% and market share gains across all brands and segments.

• Gross margin improved to 51.3% from 47.9% in the prior year period, aided by product mix and operational efficiencies.

• Operating EBITDA rose 13.7% to ₹133.5 crore, with margin at 18%.

• PAT increased by 5.7% to ₹101.7 crore compared to Q1FY24.

• Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2024.

Financial highlights

• Revenue from operations grew 8% year-over-year to ₹742 crore; consolidated revenue was ₹74,181 lacs, up from ₹68,710 lacs.

• Operating EBITDA margin expanded to 18% from 17.1% last year.

• PAT margin slightly decreased to 13.7% from 14% year-over-year.

• A&P spend increased by 22.1% to ₹61.6 crore, now 8.3% of net sales.

• Modern trade and e-commerce now contribute 15% of topline, up from 10% two to three years ago.

Outlook and guidance

• Annual double-digit sales growth is targeted, primarily led by volume, with a focus on sustaining or improving historical EBITDA margins of 16%-17%.

• Increased investments in brand building, direct distribution, and digital activities are planned.

• Margin profile could improve further over the medium term as HI losses reduce and personal care profitability rises.

• Margin acceleration is expected to be reinvested for sustainable long-term growth.

• No immediate price increases planned; current focus remains on volume growth and brand investment.